Abstract
The successful application of boron neutron capture therapy (BNCT) for melanoma depends on the following points, (1) high accumulation of 10B in target melanoma cells (approcimately 20 ppm) and (2) high tumor/normal tissue10B ratio, theoretically greater than 5.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Mishima Y, Honda C, Ichihashi M, et al: Treatment of malignant manoma by single thermal neutron capture therapy with melanoma-seeking 10B- compound. Lancet 2:388, 1989.
Hori Y, Nakamura K, Matsuoka M et al: Determination of 10B in biological samples by ICP-AES and IPC-MS. The 4th Japan-Australia International Workshop on Thermal Neutron Capture Therapy for Malignant Melanoma, Kobe, Feb. 13–17, 1989.
Ichihashi M, Sasase A,,iramoto T, et al: RBE of thermal neutron capture therapy using 10B1-paraboronophynelalanine for human and B-16 melanoma cells. Strahlen und Onkologie 165:198, 1989.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1992 Springer Science+Business Media New York
About this chapter
Cite this chapter
Ichihashi, M. et al. (1992). Further in Vitro Radiobiological Analysis on 10B-BPA BNCT of Malignant Melanoma: Correlation of Determined 10B-Content and Cell Killing Effect. In: Allen, B.J., Moore, D.E., Harrington, B.V. (eds) Progress in Neutron Capture Therapy for Cancer. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-3384-9_77
Download citation
DOI: https://doi.org/10.1007/978-1-4615-3384-9_77
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-6494-8
Online ISBN: 978-1-4615-3384-9
eBook Packages: Springer Book Archive